Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Medicinal Chemistry

• Publication date

  2010-09-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/092986710792927886PMID 20738248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toward a Consensus Model of the hERG Potassium Channel

  2010cited by this paper
• Prediction of membrane protein structures with complex topologies using limited constraints

  2009cited by this paper
• Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.

  2009cited by this paper
• Electrophysiologic characterization of a novel hERG channel activator.

  2009cited by this paper
• The Pore Domain Outer Helix Contributes to Both Activation and Inactivation of the hERG K+ Channel*

  2009cited by this paper
• Interactions of H562 in the S5 helix with T618 and S621 in the pore helix are important determinants of hERG1 potassium channel structure and function.

  2009cited by this paper
• hERG-related drug toxicity and models for predicting hERG liability and QT prolongation

  2009cited by this paper
• GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.

  2009cited by this paper
• Probing the Binding Sites and Mechanisms of Action of Two Human Ether-a-go-go-Related Gene Channel Activators, 1,3-bis-(2-Hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243)

  2008cited by this paper
• Structural Basis for Ether-a-go-go-Related Gene K+ Channel Subtype-Dependent Activation by Niflumic Acid

  2008cited by this paper
• The hERG K+ channel: target and antitarget strategies in drug development.

  2008cited by this paper
• Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.

  2008cited by this paper
• 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic Acid (PD-307243) Causes Instantaneous Current through Human Ether-a-go-go-Related Gene Potassium Channels

  2008cited by this paper
• hERG: the long and short of it.

  2008cited by this paper
• Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.

  2008cited by this paper
• Role of hERG potassium channel assays in drug development

  2008cited by this paper
• The hERG potassium channel and hERG screening for drug-induced torsades de pointes.

  2008cited by this paper
• Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies

  2008cited by this paper
• Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-à-go-go-Related Gene Channels

  2008cited by this paper
• Drugs and trafficking of ion channels: a new pro‐arrhythmic threat on the horizon?

  2008cited by this paper
• Modeling hERG and its Interactions with Drugs: Recent Advances in Light of Current Potassium Channel Simulations

  2008cited by this paper
• Activation Gating of hERG Potassium Channels

  2007cited by this paper
• State-dependent dissociation of HERG channel inhibitors

  2007cited by this paper
• Molecular dynamics and continuum electrostatics studies of inactivation in the HERG potassium channel.

  2007cited by this paper
• Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR.

  2007cited by this paper
• Membrane protein structure: prediction versus reality.

  2007cited by this paper
• Closing in on the resting state of the Shaker K(+) channel.

  2007cited by this paper
• Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain

  2007cited by this paper
• hERG channel trafficking: novel targets in drug-induced long QT syndrome.

  2007cited by this paper
• Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment

  2007cited by this paper
• A novel structure-based virtual screening model for the hERG channel blockers.

  2007cited by this paper
• A quantitative assessment of hERG liability as a function of lipophilicity.

  2007cited by this paper
• Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator

  2007cited by this paper
• Drug block of the hERG potassium channel: Insight from modeling

  2007cited by this paper
• Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1.

  2007cited by this paper
• Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists--Increasing selectivity over hERG.

  2007cited by this paper
• In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.

  2007cited by this paper
• HERG is protected from pharmacological block by alpha-1,2-glucosyltransferase function.

  2007cited by this paper
• Impact of ancillary subunits on ventricular repolarization.

  2007cited by this paper
• Dynamics of the Kv1.2 voltage-gated K+ channel in a membrane environment.

  2007cited by this paper
• Predictive models for HERG channel blockers: ligand-based and structure-based approaches.

  2007cited by this paper
• Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.

  2007cited by this paper
• Molecular Mapping of the Binding Site for a Blocker of Hyperpolarization-Activated, Cyclic Nucleotide-Modulated Pacemaker Channels

  2007cited by this paper
• hERG potassium channels and cardiac arrhythmia

  2006cited by this paper
• Determination of hERG channel blockers using a decision tree.

  2006cited by this paper
• An Accurate and Interpretable Bayesian Classification Model for Prediction of hERG Liability

  2006cited by this paper
• From molecule to malady

  2006cited by this paper
• Quantitative Structure-Activity Relationship Studies on Inhibition of HERG Potassium Channels

  2006cited by this paper
• Development and Evaluation of an in Silico Model for hERG Binding

  2006cited by this paper
• Innovative approaches to anti-arrhythmic drug therapy

  2006cited by this paper
• Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator

  2006cited by this paper
• Voltage sensor conformations in the open and closed states in ROSETTA structural models of K(+) channels.

  2006cited by this paper
• A novel hypothesis for the binding mode of HERG channel blockers.

  2006cited by this paper
• Dynamics of K+ ion conduction through Kv1.2.

  2006cited by this paper
• New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.

  2006cited by this paper
• Medicinal chemistry of hERG optimizations: Highlights and hang-ups.

  2006cited by this paper
• Mallotoxin Is a Novel Human Ether-a-go-go-Related Gene (hERG) Potassium Channel Activator

  2006cited by this paper
• Evaluation of the Rabbit Purkinje Fibre Assay as an in vitro Tool for Assessing the Risk of Drug-Induced Torsades de Pointes in Humans

  2006cited by this paper
• Pharmacogenetics and cardiac ion channels.

  2006cited by this paper
• Drug‐induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine

  2006cited by this paper
• Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels.

  2006cited by this paper
• Molecular Determinants of hERG Channel Block

  2006cited by this paper
• In Silico Classification of hERG Channel Blockers: a Knowledge‐Based Strategy

  2006cited by this paper
• Biophysical Characterization of the New Human Ether-A-Go-Go-Related Gene Channel Opener NS3623 [N-(4-Bromo-2-(1H-tetrazol-5-yl)-phenyl)-N′-(3′-trifluoromethylphenyl)urea]

  2006cited by this paper
• Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs

  2006cited by this paper
• On Outliers and Activity Cliffs-Why QSAR Often Disappoints

  2006cited by this paper
• Multipass membrane protein structure prediction using Rosetta

  2005cited by this paper
• Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C.

  2005cited by this paper
• Crystal Structure of a Mammalian Voltage-Dependent Shaker Family K+ Channel

  2005cited by this paper
• Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods

  2005cited by this paper
• A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.

  2005cited by this paper
• Voltage Sensor of Kv1.2: Structural Basis of Electromechanical Coupling

  2005cited by this paper
• Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels.

  2005cited by this paper
• Molecular mapping of a site for Cd2+‐induced modification of human ether‐à‐go‐go‐related gene (hERG) channel activation

  2005cited by this paper
• Activators of Cation Channels: Potential in Treatment of Channelopathies

  2005cited by this paper
• QT interval prolongation: and the beat goes on.

  2005cited by this paper
• A two-state homology model of the hERG K+ channel: application to ligand binding.

  2005cited by this paper
• Drug‐induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics

  2005cited by this paper
• Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel

  2005cited by this paper
• QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development

  2005cited by this paper
• Novel Potent Human Ether-à-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity

  2005cited by this paper
• Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition

  2005cited by this paper
• Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

  2005cited by this paper
• Detection of drug-induced proarrhythmia: balancing preclinical and clinical studies.

  2005cited by this paper
• In silico modelling of ADMET—a minireview of work from 2000 to 2004

  2005cited by this paper
• Dynamic conformational changes of extracellular S5–P linkers in the hERG channel

  2005cited by this paper
• Sarcolemmal K(ATP) channels: what do we really know?

  2005cited by this paper
• Predictive models for hERG potassium channel blockers.

  2005cited by this paper
• Protein trafficking abnormalities: a new mechanism in drug‐induced long QT syndrome

  2005cited by this paper
• Predictive in silico modeling for hERG channel blockers.

  2005cited by this paper
• High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.

  2004cited by this paper
• A model for identifying HERG K+ channel blockers.

  2004cited by this paper
• Prolonged repolarization and triggered activity induced by adenoviral expression of HERG N629D in cardiomyocytes derived from stem cells.

  2004cited by this paper
• Micro-Electrode Arrays in Cardiac Safety Pharmacology

  2004cited by this paper
• Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands

  2004cited by this paper
• Drug‐induced QT interval prolongation: regulatory perspectives and drug development

  2004cited by this paper
• The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping

  2004cited by this paper
• Drugs, hERG and sudden death.

  2004cited by this paper
• Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.

  2004cited by this paper
• HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study.

  2004cited by this paper

• Toward Natural Products-Based Drug Development for Erectile Dysfunction: A Molecular Candidate from Plant Tribulus terrestris Identified by an Integrated In Silico Study

  2025cites this paper
• Utilizing Heteroatom Types and Numbers from Extensive Ligand Libraries to Develop Novel hERG Blocker QSAR Models Using Machine Learning-Based Classifiers

  2023cites this paper
• hERG Blockade Prediction by Combining Site Identification by Ligand Competitive Saturation and Physicochemical Properties

  2022cites this paper
• The ERG1 K+ Channel and Its Role in Neuronal Health and Disease

  2022cites this paper
• Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity

  2021cites this paper
• Part-II- in silico drug design: application and success

  2021cites this paper
• Computational Intelligence Methods for Bioinformatics and Biostatistics: 15th International Meeting, CIBB 2018, Caparica, Portugal, September 6–8, 2018, Revised Selected Papers

  2020cites this paper
• Virtual Screening Based on Pharmacophore to Discover Host ER Alpha-Glucosidase II Inhibitor for Dengue Therapy

  2020cites this paper
• Assessing hERG1 Blockade from Bayesian Machine-Learning-Optimized Site Identification by Ligand Competitive Saturation Simulations

  2020cites this paper
• Screening of terpenoids as potential therapeutics against Zaire ebolavirus infection through pharmacophore-based drug design

  2019cites this paper
• Screening of terpenoids as potential therapeutics against Zaire infection through pharmacophore-based drug design ebolavirus

  2019cites this paper
• Atomistic modeling towards predictive cardiotoxicity

  2019cites this paper
• Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPARδ modulators.

  2019cites this paper
• Inhibition of Primed Ebola Virus Glycoprotein by Peptide Compound Conjugated to HIV-1 Tat Peptide Through a Virtual Screening Approach

  2018cites this paper
• Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation.

  2018cites this paper
• Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.

  2018cites this paper
• Binding modes of hERG blockers: an unsolved mystery in the drug design arena

  2018cites this paper
• Computational Approaches for PredictinghERGActivity

  2018cites this paper
• Development of Safe Drugs: The hERG Challenge

  2018cites this paper
• Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development

  2017cites this paper
• Atomistic molecular dynamics simulations of typical and atypical antipsychotic drugs at the dopamine D2 receptor (D2R) elucidates their inhibition mechanism

  2017cites this paper
• Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity

  2017cites this paper
• A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal‐induced arrhythmias

  2017cites this paper
• In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors

  2017cites this paper
• Structural investigation of vesnarinone at the pore domains of open and open-inactivated states of hERG1 K+ channel.

  2017cites this paper
• First universal pharmacophore model for hERG1 K+ channel activators: acthER.

  2017cites this paper
• Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics

  2017cites this paper
• Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.

  2017cites this paper
• Role of the pH in state-dependent blockade of hERG currents

  2016cites this paper
• New potential binding determinant for hERG channel inhibitors

  2016cites this paper
• In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors

  2016cites this paper
• An antiarrhythmic agent as a promising lead compound for targeting the hEAG1 ion channel in cancer therapy: insights from molecular dynamics simulations

  2016cites this paper
• Novel strategies to overcome Cisplatin resistance in colorectal cancer.

  2016cites this paper
• Computational Modeling of Cardiac K + Channels and Channelopathies

  2016cites this paper
• Diversity and functional roles of K + channels in cardiac repolarization : from single cell to whole organ levels

  2016cites this paper
• In silico prediction of hERG inhibition.

  2015cites this paper
• ADMET Prediction Based on Protein Structures

  2014cites this paper
• Designing of multi-targeted molecules using combination of molecular screening and in silico drug cardiotoxicity prediction approaches.

  2014cites this paper
• Inhibition of mammalian carbonic anhydrases I-XIV with grayanotoxin III: solution and in silico studies

  2014cites this paper
• Rehabilitating drug-induced long-QT promoters: In-silico design of hERG-neutral cisapride analogues with retained pharmacological activity

  2014cites this paper
• Molecular mechanisms of DNA translocation through a biological nanopore alpha-hemolysin

  2014cites this paper
• Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools

  2014cites this paper
• DEVELOPMENT AND APPLICATIONS OF GLOBAL ADMET MODELS

  2013cites this paper
• Indexing molecules for their hERG liability.

  2013cites this paper
• Regulation of transport in the connecting tubule and cortical collecting duct.

  2012cites this paper
• Structure-Guided Topographic Mapping and Mutagenesis to Elucidate Binding Sites for the Human Ether-a-Go-Go-Related Gene 1 Potassium Channel (KCNH2) Activator NS1643

  2012cites this paper
• Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding

  2012cites this paper
• γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.

  2012cites this paper
• Recherche de facteurs génétiques intervenant dans la variabilité de la réponse aux opioïdes dans le traitement de la douleur et les traitements de substitution

  2012cites this paper
• A Molecular Switch Driving Inactivation in the Cardiac K+ Channel hERG

  2012cites this paper
• Ion channels and their inhibitors

  2011cites this paper
• hERG Potassium Channels in Drug Discovery and Development

  2011cites this paper
• The discovery of novel cyclohexylamide CCR2 antagonists.

  2011cites this paper
• Atomistic models for free energy evaluation of drug binding to membrane proteins.

  2011cites this paper
• Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson–Boltzmann surface area calculations

  2011cites this paper
• In silico Analysis of Conformational Changes Induced by Mutation of Aromatic Binding Residues: Consequences for Drug Binding in the hERG K+ Channel

  2011cites this paper
• Structural refinement of the hERG1 pore and voltage‐sensing domains with ROSETTA‐membrane and molecular dynamics simulations

  2010cites this paper